News >

Engineering Immune Response With In-Situ Vaccines in iNHL

Caroline Seymour
Published: Thursday, Mar 26, 2020

Joshua Brody, MD

Joshua Brody, MD

In-situ vaccines could be a novel way to harness immune response and extend the reach of immunotherapy, explained Joshua Brody, MD, citing a study in Nature Medicine, which showed antitumor T-cell responses in patients with advanced-stage indolent non-Hodgkin lymphoma.

In the study, investigators injected Flt3 ligand, radiotherapy, and a TLR3 agonist into lymphoma cells, drawing antigen-loaded and activated dendritic cells to the tumor.

“There’s no question that the immune system has the ability to get rid of our patients’ tumors and provide long remissions. We shouldn't shy away from [imagining] cures either,” said Brody. “All we need to do is optimize how we teach the immune system to recognize lymphoma cells and how to avoid some of these resistance mechanisms.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication